Statement of the active substances and other ingredients

Each ml contains:

Active substance: Marbofloxacin 100.0mg

Excipients:
- Metacresol 2.0mg
- Monothioglycerol 1.0mg
- Disodium edetate 0.1mg

Clear, yellowish solution.

Indications

**In cattle:**
- Treatment of respiratory infections caused by sensitive strains of *Pasteurella multocida, Mannheimia haemolytica, Histophilus somni* and *Mycoplasma bovis*.
- Treatment of acute mastitis caused by *E.coli* strains sensitive to marbofloxacin during the lactation period.

**In pigs:**
- Treatment of Metritis Mastitis Agalactia syndrome (postpartum dysgalactiae syndrome, PDS) caused by susceptible strains of organisms.

Contraindications

Do not use in animals with known hypersensitivity to marbofloxacin or to any other quinolone or to any of the excipients.

Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).

Adverse reactions

Intramuscular or subcutaneous injections are well tolerated although transitory inflammatory lesions without clinical impact can occur at the injection site. Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site and inflammatory lesions which may persist for at least 12 days after injection. No other adverse effect was observed on cattle.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

Target species

Cattle and pigs.

Dosage for each species, routes and method of administration

To ensure administration of the correct dose, body weight should be determined as accurately as possible, to avoid underdosing.

**Cattle:** Respiratory infections
- This product may be administered as a single dose given on one day only or as a multiple dose injection given over 3-5 days.
- **Single dose – Intramuscular use:** The recommended dosage is 8mg/kg bodyweight (i.e. 2ml of product/25kg bodyweight in a single injection). This optimised dosing regimen should be considered as the dosing regimen of choice in the treatment of cattle respiratory disease with the exception of the situations listed below.
- **Multiple dose – Intramuscular, intravenous or subcutaneous use:** The recommended dosage is 2mg/kg bodyweight (i.e. 1ml of product/50kg bodyweight in a single daily injection for 3-5 days). This dosing regimen should be used for treatment of specific cases such as those which require intravenous treatment or infections caused by *Mycoplasma bovis*.

**Cattle:** Acute mastitis
- **Intramuscular or subcutaneous use:** The recommended dosage is 2mg/kg bodyweight (i.e. 1ml of product/50kg bodyweight in a single daily injection, for 3 consecutive days). The first injection may also be given by the intravenous route.
- **Pigs (sows):** Intramuscular use: The recommended dosage is 2mg/kg bodyweight (i.e. 1ml of product/50kg bodyweight in a single daily injection, for 3 consecutive days).

Advice on correct administration

If the volume to be injected is more than 20ml, it should be divided between two or more injection sites.

It is preferable to inject cattle and pigs in the neck.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured. Do not broach the 100ml vial more than 25 times and a 250ml vial more than 50 times.

Withdrawal period

Withdrawal period:
- **Cattle 2mg/kg for 3 to 5 days (IV/IM/SC):**
  - Meat and offal: 6 days, Milk: 36 hrs
  - Cattle 8mg/kg on a single occasion (IM):
    - Meat and offal: 3 days, Milk: 72 hrs
    - Pigs, Meat and offal: 4 days

**Pigs:** Meat and offal: 4 days

Special storage precautions

Keep out of the reach and sight of children.

Do not use after the expiry date stated on the label.

Shelf-life after first opening the immediate packaging (20, 50, 100, 250ml vials): 28 days.

When the container is broached (opened) for the first time, using the in-use shelf-life which is specified on this package leaflet, the date on which any product remaining in the container should be discarded should be worked out. This discard date should be written in the space provided on the carton/label.

Keep the container in the outer carton in order to protect from light.

For the 10ml vial only:
- Vial must be used immediately after opening. Following withdrawal of the required dose, the remainder of the contents of the vial should be discarded.

---

**marbocare® 100mg/ml**

Solution for Injection for Cattle and Pigs

Marbofloxacin
For animal treatment only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

- People with known hypersensitivity to (fluoro)quinolones should avoid any contact with the product.
- If the product comes into contact with the skin or eyes, rinse with large amounts of water.
- Avoid accidental self-injection, since this can cause local irritation.
- Wash hands after use.
- In case of accidental self-injection or ingestion, seek medical advice immediately and show package leaflet or the label to the physician.

Use during pregnancy or lactation

Laboratory studies in the rat and rabbit have not produced any evidence of a teratogenic, foetotoxic or maternotoxic effect.

Dose of 2mg/kg body weight:
Safety of the product has been established in pregnant and lactating cows and sows.

Dose of 8mg/kg body weight:
Safety of the product has been established in pregnant cows or in suckling calves when used in the cow. Therefore, this dose regimen should be used only according to the benefit/risk assessment by the responsible veterinarian.

Overdose (symptoms, emergency procedures, antidotes), if necessary

No severe side effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively.

Overdosage may cause acute signs in the form of neurological disorders which would have to be treated symptomatically.

Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

Special precautions for the disposal of unused veterinary medicinal product or waste material, if any:

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

Date on which the package leaflet was last approved: 26.09.12

Other information
For animal treatment only.

Pharmacodynamic properties

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group. It acts by inhibition of DNA gyrase and shows concentration dependent bactericidal activity. It has a broad-spectrum activity against Gram-positive bacteria and Gram-negative bacteria (e.g. Pasteurella multocida, Mannheimia haemolytica, Histophilus somni, E. coli) as well as against mycoplasmas (Mycoplasma bovis).

The marbofloxacin in vitro activity against pathogens isolated in 2004 from bovine respiratory diseases during a clinical field trial in France, Germany, Spain and Belgium, is good. MIC values are comprised between 0.015 and 0.25μg/ml for M. haemolytica (MIC50 = 0.124μg/ml; MIC90 = 0.009μg/ml) and 0.004 and 0.12μg/ml for P. multocida (MIC50 = 0.022μg/ml; MIC90 = 0.009μg/ml) and between 0.015 and 0.29μg/ml for Histophilus somni. Strains with MIC ≥ 1μg/ml are sensitive to marbofloxacin whereas strains with MIC ≥ 4μg/ml are resistant to marbofloxacin.

Resistance to fluoroquinolones occurs mostly by chromosomal mutation with three mechanisms: decrease of the bacterial wall permeability, expression of efflux pump or mutation of enzymes responsible for molecule binding.

Pharmacokinetic particulars

After subcutaneous or intramuscular administration in cattle and intramuscular administration in pigs at the recommended dose of 2mg/kg body weight, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5μg/ml within less than 1 hour. Its bioavailability is close to 100%.

After a single intramuscular administration in cattle at the recommended dose of 8mg/kg body weight, the maximum plasma concentration of marbofloxacin (Cmax) is 7.3μg/ml reached in = 0.78h (Tmax). Binding to plasma proteins is about 30%. Marbofloxacin is eliminated slowly (½β = 15.60 h), predominantly in the active form in urine and faeces.

It is weakly bound to plasma proteins (less than 10% in pigs and 30% in cattle), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract) it achieves a higher concentration than in plasma.

In cattle, marbofloxacin is eliminated in pre-eliminating calves (½β = 5-9%) but faster in ruminant cattle (½β = 4-7%) predominantly in the active form in urine (3/4 in pre-eliminating calves, 1/2 in ruminants) and faeces (1/4 in pre-eliminating calves, 1/2 in ruminants). In pigs, marbofloxacin is eliminated slowly (½β = 8-10h) predominantly in the active form in urine (2/3) and faeces (1/3).

Pack sizes

Packaged in Amber Type II glass vials of 10, 20, 50, 100 and 250ml. Not all pack sizes may be marketed.